US4261973A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Allergen-containing substances
Assignee: Pfizer Health AB
•
Filing: 1977-08-08
•
Granted: 1981-04-14
•
Expires: 1997-08-08
Abstract
Abstract This invention pertains to allergen-containing substances, methods of preparing the same and using the same as immunologically specific suppressants of the production of reaginic antibodies directed to the allergen in question. The allergen-containing substances can be characterized as covalent conjugates of the allergen molecules with non-immunogenic water-soluble polymers. The degree of conjugation is such that the conjugates are rendered tolerogenic as well as substantially non-allergenic and non-immunogenic. The new conjugates are useful for immunologically specific suppression of common allergies in mammals, including humans, which are mediated by reaginic antibodies of the IgE class.
Inventors
- 👤 Weng Y. Lee
- 👤 Alec Sehon
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 06:54
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/35; A61K39/36; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/59; A61K47/60; A61K2039/60; A61K2039/6093; Y; Y10; Y10S; Y10S424/00; Y10S424/805; Y10S424/81
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
67 words
The method for immunologically specific suppressing of the production of reaginic antibodies directed to the allergen in question which comprises injecting into mammals suffering from an allergy a therapeutically efficient dose, and in a pharmaceutically acceptable manner, at least one allergen-containing substance being characterized as covalent conjugates of immungenic allergen molecules with non-immunogenic water-soluble polymers, the degree of conjugation being such that the conjugates are rendered tolerogenic.
Claim 2
Independent Claim
67 words
The method for immunologically specific suppressing of the production of reaginic antibodies directed to the allergen in question which comprises injecting into mammals suffering from an allergy a therapeutically efficient dose, and in a pharmaceutically acceptable manner, at least one allergen-containing substance being characterized as covalent conjugates of immungenic allergen molecules with non-immunogenic water-soluble polymers, the degree of conjugation being such that the conjugates are rendered tolerogenic.
Claim 3
Dependent Claim
28 words
The method as set forth in claim 1 wherein the polymer of the conjugate is a polyethylene glycol having a molecular weight of about 2,000 to about 35,000.
Claim 4
Dependent Claim
29 words
The method as set forth in claim 1 wherein the polymer of the conjugate is selected from the group consisting of polyvinylalcohols, polyvinylpyrrolidones, polyacrylamides and homopolymers of amino acids.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-04-13 | 1984-10-13 | 1985-04-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-04-13 | 1988-10-13 | 1989-04-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-04-13 | 1992-10-13 | 1993-04-14 | $7700.00 | Window Closed / Lapsed |